-- Originally posted on: https://steroiduck.com/ment-trestolone-in-bodybuilding/
Important Disclaimer: This article is for educational and informational purposes only. It is not medical advice and does not encourage or endorse the non-medical, illicit, or experimental use of trestolone (MENT, 7α-methyl-19-nortestosterone). Trestolone is an investigational compound that has never been approved by the FDA or equivalent agencies for any human therapeutic use. It is a Schedule III controlled substance in the United States and is prohibited by WADA in sports. Non-medical use carries substantial risks, including profound suppression of natural testosterone production, estrogenic effects, cardiovascular strain, infertility, and other long-term health consequences. Any use must occur only under strict medical supervision with regular laboratory monitoring. Consult a qualified healthcare professional for hormone-related issues.
What is Trestolone (MENT)?
Trestolone, also known as 7α-methyl-19-nortestosterone (MENT), is a potent synthetic 19-nor androgen developed primarily for research into male hormonal contraception and androgen replacement therapy in hypogonadal men. It remains experimental and has not been marketed for clinical use.
Chemical profile: Formula C₁₉H₂₈O₂. It features a methyl group at the 7α position, conferring high androgen receptor affinity, resistance to 5α-reductase (reducing prostate stimulation relative to testosterone), and progestogenic activity. It aromatizes to a potent estrogen (7α-methylestradiol).
Legal status: Not FDA-approved. Available only as a research chemical (not for human consumption). Procurement and use outside regulated medical channels are illegal in most jurisdictions.
How Trestolone Works
Trestolone binds strongly to androgen receptors and exhibits greater anabolic potency than testosterone in preclinical models (roughly 10-fold in some measures of muscle maintenance). It suppresses the hypothalamic-pituitary-gonadal axis dose-dependently, reducing LH, FSH, and endogenous testosterone. Its resistance to 5α-reduction may offer a wider therapeutic index for prostate effects in research settings, but it still carries estrogenic and progestogenic risks.
Pharmacokinetics: Unesterified MENT has a very short half-life (~40 minutes after IV administration) and high metabolic clearance rate (~1,790 – 2,360 L/day), with minimal SHBG binding. The acetate ester (trestolone acetate) is commonly studied for intramuscular use but still requires frequent administration due to relatively rapid release and hydrolysis to active MENT. Sustained-release implants have been explored for steadier delivery.
MENT Dosage Considerations (Research vs. Reported Use)
All dosing information derives from limited clinical research studies; there are no approved or standardized therapeutic doses.
In published human trials:
- Implants: Two subcutaneous implants, each containing 115 mg trestolone acetate, provided stable plasma MENT levels of approximately 1.3 – 1.4 nmol/L over 6 weeks. Earlier studies described implants releasing roughly 400 μg/day.
- Intramuscular injections: Single doses of 2, 4, or 8 mg MENT in aqueous suspension produced dose-dependent peak levels reached in 1 – 2 hours. Daily injections of 1, 2, or 4 mg for 6 consecutive days demonstrated potent, dose-dependent suppression of gonadotropins and testosterone (4 mg/day reduced testosterone by ~74%).
These research doses are in the microgram-to-low-milligram range per day and were used short-term under medical supervision with monitoring. The appropriate dose for any potential therapeutic application “remains to be determined.”
In non-medical contexts (e.g., bodybuilding or performance enhancement), anecdotal reports commonly cite much higher doses of trestolone acetate – typically 10 – 50 mg per day (with some advanced users exceeding this), administered via intramuscular injection. These doses are orders of magnitude higher than those studied clinically and have not been evaluated for safety or efficacy in controlled trials. Due to the short-acting nature of the acetate ester, users often inject daily or every other day to maintain levels. Such supraphysiological exposure amplifies risks of severe HPTA suppression, estrogenic side effects, and other adverse outcomes. No “safe” or optimal dosage exists for non-medical use.
Key factors influencing dosing:
- Individual response, goals, and tolerance vary widely.
- Blood work (hormones, lipids, liver function, hematocrit, estrogen/prolactin) is essential for any monitored use.
- Lower starting doses and titration are always advised in research settings; self-administration bypasses this safety framework.
MENT Cycle Considerations
Clinical studies have not used “cycles” in the bodybuilding sense. Research administrations were short-term:
- Implant studies typically lasted 4 – 6 weeks (or up to 48 weeks in one combination contraceptive trial, with declining release over time).
- Injection studies involved 6 consecutive daily doses or single administrations with follow-up.
Trestolone’s potency and rapid clearance make prolonged continuous use impractical and increasingly risky without medical oversight. Its strong antigonadotropic effects can suppress natural hormone production within days, complicating recovery.
In non-medical anecdotal reports, “cycles” are often described as 4 – 8 weeks (occasionally up to 12 weeks), reflecting the compound’s intensity and users’ desire to limit exposure. Longer durations heighten the likelihood of side effects and may require more robust post-cycle interventions. Due to the acetate ester’s pharmacokinetics, consistent daily or every-other-day injections are typical to avoid fluctuating levels.
Stacking: Anecdotal practices sometimes combine trestolone acetate with testosterone esters to mitigate full HPTA shutdown and support androgenic functions, or with other compounds for synergistic effects. However, stacking increases overall hormonal disruption, estrogenic load, and cardiovascular strain. No clinical data support these combinations for performance.
Post-Cycle Therapy (PCT): MENT’s potent suppression often necessitates a structured recovery protocol (e.g., SERMs such as tamoxifen or clomiphene) starting after clearance (typically days to weeks, depending on ester and duration). Full HPTA recovery can take months and may be incomplete, especially after higher or longer exposures. Medical supervision with serial blood tests is critical; self-managed PCT has variable success rates.
General cycle planning principles (medical context only):
- Prioritize the lowest effective exposure.
- Incorporate regular monitoring.
- Allow adequate time off between periods of use for hormonal recovery.
- Focus on diet, training, and overall health rather than relying solely on the compound.
Side Effects and Risk Management
Risks are dose- and duration-dependent and include:
- Estrogenic: Gynecomastia, fluid retention, and elevated blood pressure due to aromatization.
- Androgenic/Progestogenic: Acne, hair loss (in predisposed individuals), libido changes, and potential “Deca-like” sexual side effects.
- Endocrine: Rapid and profound testosterone suppression, reduced fertility, testicular atrophy.
- Cardiovascular: Adverse lipid shifts, hypertension.
- Other: Possible liver stress, mood alterations, and unknown long-term effects given limited human data.
Mitigation strategies (only under medical supervision) include aromatase inhibitors for estrogen control, supportive supplements (e.g., for lipids and liver), and thorough pre-, on-, and post-cycle blood work. No approach eliminates risks in non-medical use.
Conclusion
Trestolone (MENT) is a pharmacologically interesting experimental androgen with high potency and unique properties that made it a candidate for male contraception and replacement therapy research. However, its non-medical application for muscle growth or performance remains unproven, illegal, and highly hazardous. Doses and cycles reported in fitness communities far exceed those studied clinically and can lead to serious, potentially irreversible health consequences. Prioritize long-term well-being over short-term gains. For legitimate hormone concerns, seek evidence-based care from a physician using approved treatments.
Contact Info:
Name: Steroiduck
Email: Send Email
Organization: Steroiduck
Website: https://steroiduck.com/
Release ID: 89185327
If there are any errors, inconsistencies, or queries arising from the content contained within this press release that require attention or if you need assistance with a press release takedown, we kindly request that you inform us immediately by contacting error@releasecontact.com (it is important to note that this email is the authorized channel for such matters, sending multiple emails to multiple addresses does not necessarily help expedite your request). Our reliable team will be available to promptly respond within 8 hours, taking proactive measures to rectify any identified issues or providing guidance on the removal process. Ensuring accurate and dependable information is our top priority.
